A patient-centric benefit-risk assessment of daridorexant for the treatment of insomnia disorder using patient preference data collected in two phase 3 clinical trials
Publication date: December 2025 Source: Sleep Epidemiology, Volume 5 Author(s): Sebastian Heidenreich, Melissa Ross, Bruno Flamion, Andrea Phillips-Beyer
A patient-centric benefit-risk assessment of daridorexant for the treatment of insomnia disorder using patient preference data collected in two phase 3 clinical trials. // Sleep Epidemiology. – URL: https://www.sciencedirect.com/science/article/pii/S2667343625000034?dgcid=rss_sd_all
A patient-centric benefit-risk assessment of daridorexant for the treatment of insomnia disorder using patient preference data collected in two phase 3 clinical trials. Sleep Epidemiology. https://www.sciencedirect.com/science/article/pii/S2667343625000034?dgcid=rss_sd_all
“A patient-centric benefit-risk assessment of daridorexant for the treatment of insomnia disorder using patient preference data collected in two phase 3 clinical trials.” Sleep Epidemiology.
@article{article99383,
title = {A patient-centric benefit-risk assessment of daridorexant for the treatment of insomnia disorder using patient preference data collected in two phase 3 clinical trials},
journal = {Sleep Epidemiology},
url = {https://www.sciencedirect.com/science/article/pii/S2667343625000034?dgcid=rss_sd_all}
}